Syed T. Husain Appointed As The New Chief Executive Officer Of BioCentriq

BioCentriq has appointed Syed as CEO, recognizing his vast expertise in CDMO development and manufacturing. With over 20 years in strategic management and a deep grasp of cell and gene therapy, Syed has a proven history of guiding companies through rapid growth, market innovation, and industry shifts. His leadership is set to enhance BioCentriq's global strategy, market presence, team performance, operational efficiency, and financial success, all while focusing on patient-centric growth.

James Park, Chairman of the Board at BioCentriq, said, “The cell and gene therapy (CGT) sector has reached a new stage, where a range of late-stage therapies are reaching commercialisation, and a considerable number of next-generation therapies are entering and progressing through early-stage clinical development. In turn, the cell and gene therapy sector is meeting strong pressures on the investment required for high development and product manufacturing costs, increasing pressure on the pricing for commercialised therapies.’ 

He also mentioned that, “To match this new stage of the CGT sector, BioCentriq is also starting the next phase of its growth, with its LEAP™ program providing a badly needed solution to the market and its concentration on early to mid-phase therapeutic development. Syed’s extensive experience in CDMO business expansion will be pivotal in ensuring BioCentriq’s leadership in manufacturing innovation and in spearheading the clinical to commercial manufacturing of cutting-edge cell therapies.”

Syed’s deep industry knowledge will steer BioCentriq through its upcoming growth phase, positioning the company to effectively serve pharma and biotech clients as they transition to critical and commercial manufacturing stages while still meeting their development and clinical supply requirements. Drawing on his recent role as Chief Commercial Officer at Resilience, Syed honed an exceptional commercial team, adept in both established areas like Biologics and Vaccines, and emerging fields such as Cell & Gene Therapy and Nucleic Acids. 

His tenure saw the creation of a multi-billion-dollar pipeline and the securing of pivotal deals with leading pharmaceutical and biotech firms. Syed also cultivated a customer-focused culture that greatly enhanced client satisfaction and supported sustainable, patient-centered growth. Before his achievements at Resilience, he held leadership positions in CDMOs including Emergent BioSolutions, Alcami Corporation, and Lonza.

Syed T. Husain commented, “BioCentriq has quickly developed a unique offering to the U.S. and global CGT manufacturing space, backed by strong partnerships that significantly cut development and technology transfer timelines. We offer the CGT market the flexibility of a mid-sized, entrepreneurial CDMO with a proven track record. This will be crucial in scaling the next generation of therapies to reach broader patient populations.” 

He further added, “As BioCentriq moves into its next phase of growth, we’re committed to strengthening our capabilities even further. Our goal is to drive the approval of new CGT modalities by offering a complete end-to-end solution — from clinical to commercial manufacturing, ensuring that life-changing therapies reach the patients who need them most.”